Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis.
Journal: The oncologist
Published: December 29, 2023
UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan.
Journal: Cancer medicine
Published: December 13, 2023
Tumor heterogeneity and clinically invisible micrometastases in metastatic breast cancer-a call for enhanced surveillance strategies.
Journal: NPJ precision oncology
Published: September 14, 2023
Organ-Specific Immune Setpoints Underlie Divergent Immune Profiles across Metastatic Sites in Breast Cancer.
Journal: Cancer immunology research
Published: August 30, 2023
PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer.
Journal: Cell reports. Medicine
Published: August 02, 2023
Tumor draining lymph nodes connected to cold triple-negative breast cancers are characterized by Th2-associated microenvironment.
Journal: Nature communications
Published: March 30, 2023
Hyperglycemia and Glycemic Variability Associated with Glucocorticoids in Women without Pre-Existing Diabetes Undergoing Neoadjuvant or Adjuvant Taxane Chemotherapy for Early-Stage Breast Cancer.
Journal: Journal of clinical medicine
Published: February 09, 2023
HER2-targeted antibody-drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia.
Journal: Breast cancer (Tokyo, Japan)
Published: February 02, 2023
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.
Journal: The oncologist
Published: September 07, 2022
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: August 18, 2022
Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Journal: Cancer
Published: August 09, 2022
Last Updated: 09/26/2026